Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease

Donald P Tashkin¹
Michael E Wechsler²
¹Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; ²Department of Medicine, National Jewish Health, Denver, CO, USA

Abstract: COPD is a significant cause of morbidity and mortality. In some patients with COPD, eosinophils contribute to inflammation that promotes airway obstruction; approximately a third of stable COPD patients have evidence of eosinophilic inflammation. Although the eosinophil threshold associated with clinical relevance in patients with COPD is currently subject to debate, eosinophil counts hold potential as biomarkers to guide therapy. In particular, eosinophil counts may be useful in assessing which patients may benefit from inhaled corticosteroid therapy, particularly regarding exacerbation prevention. In addition, several therapies targeting eosinophilic inflammation are available or in development, including monoclonal antibodies targeting the IL5 ligand, the IL5 receptor, IL4, and IL13. The goal of this review was to describe the biologic characteristics of eosinophils, their role in COPD during exacerbations and stable disease, and their use as biomarkers to aid treatment decisions. We also propose an algorithm for inhaled corticosteroid use, taking into consideration eosinophil counts and pneumonia history, and emerging eosinophil-targeted therapies in COPD.

Keywords: lung disease, pulmonary diseases, corticosteroids, asthma, pneumonia

Introduction

COPD is a major cause of morbidity and mortality, and is predicted to be the third-leading cause of death worldwide by 2020.¹ Health-care costs rise significantly with increased severity of COPD symptoms and exacerbations.¹ COPD is characterized by persistent, progressive airflow limitation associated with chronic inflammation that is responsible for permanent structural changes to the airway and lungs. These include airway narrowing due to increased wall thickness, mucus occlusion, and destruction of lung parenchyma with loss of lung elasticity.¹,²

The underlying pattern of inflammation in COPD can vary; most often it is predominated by neutrophils, cytotoxic CD8⁺ T cells, and alveolar macrophages.² Eosinophils may play a significant role in airway inflammation in some patients with COPD.³ While eosinophilic inflammation is most often associated with asthma and has been used to differentiate asthma from COPD,³ some studies indicate that approximately a third of patients with COPD have sputum eosinophilia,⁴–⁷ with prevalence dependent on the eosinophil threshold used and the specific patient population studied. In addition, eosinophil counts in sputum⁴ are increased during exacerbations in some patients with COPD.⁵ Importantly, sputum and/or blood eosinophilia in COPD may predict response to inhaled corticosteroids (ICSs) for prevention of exacerbations⁶,⁷ and to systemic corticosteroids (CSs) for treatment of exacerbations.⁸,⁹

This review describes the biology of eosinophils and their role in COPD airway inflammation during exacerbations and in stable disease, as well as the potential of...
eosinophils as biomarkers to inform treatment decisions for COPD patients. An algorithm for the appropriate use of ICS therapy in COPD is proposed, based on the presence of eosinophils and whether or not a history of pneumonia exists, and the potential role of emerging eosinophil-targeted therapies in COPD is also discussed.

We used a PubMed search from January 1970 through October 2017, with Boolean search terms “eosinophil OR eosinophilia” AND “chronic obstructive pulmonary disease OR asthma”. This core search phrase was modified to include “AND biologics”, “AND pneumonia”, “AND (sputum OR blood)”, or “AND corticosteroid”. Searches were also conducted on ClinicalTrials.gov for “chronic obstructive pulmonary disease” (or “COPD”), “eosinophil”, “biologic” (or “biologic therapy”), or “asthma”, “eosinophil”, and “biologics” (or “biologic therapy”); the term “phase III” was also used to qualify searches. For web-based searches, terms included “eosinophil”, “blood cell”, and “quantification”.

**Eosinophils: characteristics and methods of quantification**

Eosinophils are key immunoeffector and inflammatory cells. They have diverse functions, with roles in homeostasis and disease in various tissues, including the lungs. Eosinophils are derived from progenitor stem cells in the bone marrow that are released into the blood upon maturity.

Under normal conditions, eosinophils remain quiescent in the blood; upon exposure to proinflammatory mediators (IL3, IL5, and granulocyte-macrophage colony-stimulating factor; see Figure 1), they may become partially activated before migrating to sites of inflammation. IL5 is one of the major cytokines involved in eosinophil-mediated inflammation: it promotes the differentiation, survival, trafficking, activation, and effector functions of eosinophils. Migration of eosinophils to the lungs is controlled by specific chemotactic factors, such as CCL5 (RANTES), CCL7 (MCP3), CCL11 (eotaxin 1), CCL13 (MCP-4), CCL15, CCL24, and CCL26 acting on the CCR3, along with CRTH2, which is expressed on T-helper 2 cells and its ligand, prostaglandin D2 (Figure 1). Once in the lungs, proinflammatory mediators, including basic proteins (major basic protein, eosinophil cationic protein, eosinophil peroxidase, and eosinophil-derived neurotoxin), cytokines (IL2, IL3, IL4, IL5, IL10, IL12, IL13, IL16, IL25), chemokines (CCL5, CCL11, CCL13), and growth factors (tumor necrosis factor [TNF], transforming growth factor [TGF]α/β), that are released by eosinophils contribute to sustained inflammation and tissue damage.

In addition, thymic stromal lymphopoietin, an IL7-like proallergic cytokine associated with chronic airway-disease inflammation, can act on eosinophils to upregulate inflammatory cytokine expression.

Blood eosinophil concentration is reported as an absolute count (cells/µL) or as a percentage of total leukocytes; studies show that these two quantification methods are concordant.

Eosinophil concentrations in the lungs can also be measured using induced sputum or bronchoalveolar lavage (BAL) fluid.

---

**Figure 1** Eosinophil trafficking from bone marrow to airway.

**Notes:** Eosinophil activity occurs in tissue. Mature eosinophils leave bone marrow, circulate in blood, and migrate to tissue under the influence of various chemotactic factors. Infiltration into the airways is mediated through adhesion and transmigration across the bronchial vascular epithelium. Chemokines, such as CCL5 and CCL11, and other factors play roles in this process. Reprinted with permission of Sage Publications, Ltd. George L, Brightling CE. Therapeutic Advances in Chronic Disease. 2016;7(1):34–51, Copyright 2016.

**Abbreviation:** GM-CSF, granulocyte-macrophage colony-stimulating factor.
or by quantifying eosinophils in a biopsy of lung tissue. Counts are reported as the percentage of eosinophils of total leukocytes in sputum and BAL fluid, whereas the quantification for eosinophils in biopsy specimens is expressed per specified area of tissue. Of note, these eosinophil counts reflect overall levels, and do not consider eosinophil activation.

In the general population, a wide range of eosinophil counts in blood has been reported. Recent studies have reported a median blood eosinophil count of 2.4% (of total leukocytes) in a general unselected population and absolute blood eosinophil cell counts of 100–200 cells/µL in healthy individuals. In induced sputum, mean percentages of 0.3%–1.4% have been reported for healthy nonsmokers and BAL fluid, the mean proportions of eosinophils are similar in current smokers (0.2%–0.6%) and former smokers (0.5%) and generally lower in healthy never-smokers, with a majority of reports in the range 0.07%–0.3% (but some studies reporting 0.7%–0.8% in this population). In patients with COPD, median blood eosinophil counts of 2.41%–2.70% and 180–230 cells/µL geometric mean percentages of eosinophils in induced sputum of 0.8%–6.2% and a mean percentage in BAL fluid of approximately 1.0% have been reported. In both the general population and patients with COPD, higher eosinophil levels have been found in men versus women.

**Thresholds for defining high and low eosinophils**

There is a lack of consensus on the appropriate thresholds used to define eosinophilic inflammation in COPD. Because eosinophil numbers differ during stable disease, exacerbations, and following treatment, the threshold used may depend on the study design and outcomes. In addition, blood eosinophil counts in individuals fluctuate during a 24-hour period. Therefore, it is unlikely that a single threshold will be recommended for guiding all treatment decisions. In sputum, studies have used a threshold of 1%, 2%, 3%, or 3% for defining eosinophilia in COPD, whereas studies using blood have mostly used a threshold of 2%. However, some of these thresholds (eg, 2% and 3%) were adopted from those established in studies of eosinophilia in asthma, and thus may not necessarily be the optimal threshold for COPD. In a post hoc analysis of the Withdrawal of Inhaled Steroids during Optimized Bronchodilator Management (WISDOM) study, the effect of ICS withdrawal on COPD-exacerbation rate was analyzed according to various blood eosinophil thresholds in the ranges of 150–400 cells/µL and 2%–6%. The most significant deleterious effects of ICS withdrawal on exacerbation risk were observed at thresholds of ≥4% or ≥300 cells/µL. Table 1 summarizes recent COPD trials, highlighting eosinophil thresholds used and clinical findings.

**Concordance between eosinophil counts in blood and lungs (sputum, BAL, tissue)**

Blood eosinophil concentrations are generally thought to be reasonably good predictors of eosinophil concentrations in the airways. A study of 491 patients with asthma indicated that those with high blood eosinophilia (defined as ≥300 cells/µL) had significantly greater mean concentrations of eosinophil counts in induced sputa versus patients with mean blood eosinophil counts <300 cells/µL (11.7% vs 0.4% of leukocytes, respectively; P<0.001). Several recent COPD studies have yielded moderate to strong correlations between eosinophil counts in blood and those in sputum, with a positive predictive value (area under the curve [95% CI]) of 0.85 [0.78–0.93] (during an exacerbation) and 0.76 [0.67–0.84], depending on use of blood eosinophil thresholds of 2% or ≥3%, respectively. Blood eosinophil percentages also correlate with eosinophil counts in bronchial submucosal samples. Post hoc analysis from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) study also yielded a positive correlation between blood and sputum eosinophil counts in 138 patients with COPD who had both blood and sputum measurements performed over ≥3 visits. However, the correlation coefficients (0.24–0.40) were relatively weak. Hastie et al showed that a blood eosinophil threshold of 250 cells/µL predicted a sputum eosinophil concentration of ≥2% with a false positive rate of 50%, even with a statistically significant positive correlation between the two values. In addition, a recent study demonstrated that patients with COPD and high blood eosinophil concentrations (>250 cells/µL) had significantly more eosinophils in sputum, bronchial mucosa, and BAL fluid than those having low blood eosinophil concentrations (<150 cells/µL). Moreover, BAL aliquots from patients with high blood eosinophil concentrations, compared to those with low blood eosinophils, exhibited more markers indicative of airway inflammation and remodeling. These results suggest that blood eosinophil counts may be a simple, albeit somewhat inconsistent, predictor of increased lung-resident eosinophils. As blood is easier to obtain than airway samples, blood eosinophil counts may be more readily used in clinical practice.

In contrast to these findings, Turato et al found no correlation between tissue eosinophils assessed in resected lung tissue and blood eosinophils in patients with COPD.
Interestingly, the authors also reported that low eosinophils were, if anything, associated with worse outcomes in COPD patients than high eosinophils, possibly due to a beneficial effect of eosinophils on host defense (eosinophils have been shown to contribute to the immune response against infection via their antimicrobial function).53

The prevalence of eosinophilia in COPD patients varies depending on the threshold used for evaluation. In a meta-analysis of ten trials, 63% of patients (n=10,861) had blood eosinophil counts ≥2%.18 In the WISDOM trial, 53% of patients had ≥150 eosinophils/µL, 20% had ≥300 eosinophils/µL, and 11% had ≥400 eosinophils/µL (total number of patients with eosinophil-count data 2,420).53 In a population-based matched-cohort study, 34.9% of 39,824 COPD patients had blood eosinophil counts of ≥340 cells/µL compared with 25.8% of matched non-COPD controls (n=90,772, P<0.001); 36.4% of the COPD patients in this study had blood eosinophil counts of <2%, whereas 38.3%, 16.3%, and 9.2% had elevated blood eosinophil counts based on thresholds of 2.0%–3.9%, 4.0%–5.9%, and ≥6.0%, respectively.44

### Persistence of eosinophilia in COPD

The detection of elevated eosinophil concentrations and eosinophil-associated proinflammatory factors in the airways and blood of patients with COPD65–67 suggests that eosinophils actively contribute to inflammatory processes in these patients. However, evidence suggests that eosinophilic inflammation may not persist over time. A post hoc analysis of the ECLIPSE study found that 37.4% of patients with COPD had persistently elevated blood eosinophil counts (≥2% at baseline and years 1, 2, and 3), whereas 49% had intermittent elevation of eosinophils.4 In that analysis, the group with persistently elevated blood eosinophils was slightly older, had a higher proportion of males, and had a smaller percentage of current smokers compared with the other groups.4

In an 8-year follow-up of patients with COPD and matched non-COPD controls, the percentage of patients with COPD and persistently high eosinophil counts (≥340 cells/µL) was 80% at 6 months and 30% at 4 years, declining to 18% at 8 years.44 Over the entire follow-up period, the stability of eosinophil counts was significantly lower in patients with

---

**Table 1** Eosinophil thresholds and findings in recent COPD clinical trials

<table>
<thead>
<tr>
<th>Trial</th>
<th>Intervention</th>
<th>Eosinophil thresholds</th>
<th>Clinical findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>ECLIPSE2</td>
<td>NA</td>
<td>Blood ≥2% of total leukocytes or ≥150 cells/µL; sputum ≥2% of total leukocytes</td>
<td>Some evidence of clinical benefit in patients with blood eosinophil counts consistently ≥2% vs &lt;2% for blood and sputum counts</td>
</tr>
<tr>
<td>TRISTAN55</td>
<td>Salmeterol 50 µg BID vs fluticasone propionate 500 µg BID, vs salmeterol 50 µg + fluticasone propionate 500 µg BID, vs placebo</td>
<td>Blood ≥2% of total leukocytes</td>
<td>Greater reduction in moderate/severe exacerbation rates for patients who received ICS/LABA with ≥2% eosinophils vs &lt;2%</td>
</tr>
<tr>
<td>ISOLDE62</td>
<td>Fluticasone propionate 500 µg BID vs placebo</td>
<td>Blood ≥2% of total leukocytes</td>
<td>Patients with ≥2% eosinophils had slower rates of FEV1, decline</td>
</tr>
<tr>
<td>FLAME64</td>
<td>Indacaterol 110 µg + glycopyrronium 50 µg QD vs salmeterol 50 µg + fluticasone propionate 500 µg BID</td>
<td>Blood ≥2% of total leukocytes</td>
<td>Effect of indacaterol–glycopyrronium vs fluticasone–salmeterol on COPD exacerbations independent of baseline eosinophil count</td>
</tr>
<tr>
<td>WISDOM53</td>
<td>Tiotropium 18 µg QD, salmeterol 50 µg BID + fluticasone propionate 500 µg BID for 6 weeks, then patients were randomized to continued triple therapy or gradual withdrawal of fluticasone propionate over 12 weeks</td>
<td>Blood ≥2%, ≥4%, ≥5%, and ≥6% of total leukocytes; ≥150, 300, and ≥400 cells/µL</td>
<td>Baseline blood eosinophil counts of ≥4% or 300 cells/µL correlated with the most deleterious effect of ICS withdrawal on moderate or severe exacerbation rates in patients with severe–very severe COPD</td>
</tr>
<tr>
<td>FORWARD59</td>
<td>Beclomethasone dipropionate (100 µg)–formoterol fumarate (6 µg) BID vs formoterol fumarate 12 µg BID for 6 weeks, then patients were randomized to continued triple therapy or gradual withdrawal of formoterol fumarate over 12 weeks</td>
<td>Blood &lt;110, &lt;182, &lt;280, and &lt;280 cells/µL</td>
<td>Pattern of increasing exacerbation frequency at the highest quartile (≥280 cells/µL) in patients treated with formoterol fumarate alone</td>
</tr>
<tr>
<td>NCT01272784</td>
<td>Benralozumab 100 mg SC injection Q4W for first 3 doses, then Q8W for next five doses vs placebo</td>
<td>Blood &lt;150, &lt;200, &lt;200, &lt;300, and ≥300 cells/µL</td>
<td>Numerical but nonsignificant improvements in acute exacerbations, quality of life, and FEV1 noted in the ≥300 and ≥300 cells/µL groups</td>
</tr>
<tr>
<td>NCT0109463 and NCT01017952</td>
<td>Fluticasone furoate/vilanterol 50/25, 100/25, or 200/25 µg (QD) or vilanterol 25 µg alone (QD)</td>
<td>Blood 2.4% of total leukocytes</td>
<td>Linear relationship between eosinophil concentrations and treatment outcomes. Cluster-analysis algorithm separated the clusters close to the median percentage of blood eosinophils (2.6%)</td>
</tr>
</tbody>
</table>

**Abbreviations:** BID, bis in die (twice daily); FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; NA, not available; Q4W, every 4 weeks; Q8W, every 8 weeks; QD, once daily; SC, subcutaneous.
COPD versus controls and in patients with COPD with higher versus lower eosinophil counts (≥340 vs <340 cells/µL, respectively). The authors suggested that the decreased eosinophil-count stability seen in patients with COPD may be related to variations in disease stability (eg, exacerbations) or pharmacologic therapy (eg, oral CS courses) that would not be seen in the non-COPD controls.64

A secondary analysis of the Acute Exacerbation and Respiratory InfectionS in COPD (AERIS) cohort examined the stability of eosinophilic inflammation in COPD, and found that blood eosinophil counts ≥2% were stable (≤1 visit with count <2% allowed) over a year in 58% of patients and predicted an overall lower risk of bacterial presence at exacerbation.68 Furthermore, the subset of patients who underwent bronchoscopy in the Subpopulations And Intermediate Outcomes in COPD Study (SPIROMICS; NCT01969344)69 showed significantly increased BAL eosinophils for current smokers with COPD compared with former smokers with and without COPD, as well as current smokers without COPD.70 Other large observational studies – Genetic Epidemiology of COPD (COPDGene; NCT00608764)71 and The Novel Observational Longitudinal Study (NOVELTY; NCT02760329)72 – that are currently under way will further characterize patients with COPD and healthy volunteers and provide more insight into the eosinophil profiles of these populations.

**Eosinophilic inflammation in COPD**

**Relationship to exacerbations of COPD**

A growing body of evidence supports an association between high eosinophil concentrations and exacerbations of COPD.3,10,33,55,73 Some studies have noted greater eosinophil counts during exacerbations compared with periods of stable disease,3 while others have reported an association between greater eosinophil counts and an increased exacerbation risk.3,55,73 In a 1-year observational study in which 86 patients had 182 COPD exacerbations, four distinct clusters of exacerbation type were identified: bacterial, viral, eosinophilic, and pauci-inflammatory.76 Overall, 55% of exacerbations were bacteria-associated, 29% were virus-associated, and 28% were associated with sputum eosinophilia (descriptions were not mutually exclusive; the pauci-inflammatory cluster was defined by limited changes in inflammatory profile). The inflammatory profile associated with the eosinophilic cluster in this study included sputum CCL17, CCL13, and IL5 and serum CXCL11, and IL5.76 As noted earlier, eosinophils migrate to the lungs under the influence of cytokines (IL5 in particular) and specific chemotactic factors (such as eotaxin 1 and RANTES), along with CRTH2 and prostatlandin D2.12,17,18 (Figure 1). Once in the lungs, eosinophil-derived, proinflammatory mediators, including basic proteins, cytokines, and growth factors, promote persistent inflammation,12,14 which contributes to exacerbations. Viral and/or bacterial infections are found in a majority of exacerbations.74

Eosinophil counts vary between stable and exacerbated COPD states. In a study by Fujimoto et al, sputa from healthy nonsmokers, patients with stable COPD (no exacerbation during the 2- to 3-year study period), and patients with unstable COPD (≥1 exacerbations during the study) were examined. Among unstable COPD patients, sputa were examined during stable (defined as stable condition for ≥3 months with normal day-to-day variations and without signs of airway infection) and exacerbation phases.75 Significant increases in eosinophil concentrations were found in both stable- and unstable-COPD cohorts compared with healthy nonsmokers. Greater concentrations of eosinophil chemotactic factors were found in sputa from patients with unstable COPD during an exacerbation compared with a stable phase and compared with patients with stable COPD and healthy nonsmokers.75 In another study of patients who had an acute COPD exacerbation, those with eosinophilia (≥2% or ≥300 cells/µL) had a significantly shorter length of stay (5 days) and reduced early treatment failure rate (10.3%) compared with patients who did not have elevated eosinophils (7 days and 27.4%, respectively); however, relapse was significantly more frequent in the eosinophilic group (72% vs 42.2%).76

Evaluation of ICS efficacy for treating exacerbations in COPD patients with elevated eosinophil counts supports an association between eosinophils and exacerbations, although results between studies are conflicting. Cheng et al found in a post hoc analysis of 248 patients with COPD treated with medium-or high-dose ICS in combination with a LABA, that a higher percentage of patients with baseline (prerandomization) blood eosinophil counts ≥3% had a history of acute exacerbations with ≥1 hospitalizations in the prior year (before study start) compared with patient baseline blood eosinophil counts <3% (27.1% vs 7.4%, respectively).77 In a study of 82 patients with COPD, Siva et al found that treating patients both to minimize eosinophilic airway inflammation based on induced sputum eosinophil count (ie, adjusting ICS therapy based on predetermined eosinophil thresholds) and optimize symptom control was associated with a greater reduction in severe exacerbations compared with treating patients only to minimize symptoms78 (Figure 2). Conversely, Barnes et al found in the Inhaled Steroids in Obstructive
Lung Disease in Europe (ISOLDE) study of patients with moderate to severe COPD who received ICS treatment, that the percent reduction in the overall exacerbation rate for fluticasone propionate versus placebo was higher in patients with blood eosinophil levels <2% versus ≥2%. The difference between the results of these two studies might be attributable to differing methodologies: the Siva et al study optimized anti-inflammatory treatment based on the level of sputum eosinophils, whereas a fixed dose of ICS plus as-needed short-acting bronchodilator therapy was used in the study reported by Barnes et al. Kolsum et al recently demonstrated clear differences in markers for airway inflammation in 20 COPD patients with high blood eosinophil concentrations (>250 cells/µL) compared with 21 patients with blood eosinophil concentrations of <150 cells/µL. Although the study involved a small number of patients (n=41), it provides insight into how inflammatory processes in the lung, driven in part by eosinophils, could result in differential response in patients to ICS therapy.

Relationship to pneumonia

A few studies have examined the effect of blood eosinophil count on the incidence of pneumonia in patients with COPD. Cheng and Lin found that patients with COPD and high eosinophil levels (≥3%) responded to ICS/LABA therapy better (greater improvement in percentage-predicted forced expiratory volume in 1 second (FEV₁), quality of life, frequency of annual exacerbations) than those with concentrations <3%; however, no difference in pneumonia incidence in response to ICS/LABA treatment was observed based on high and low eosinophil concentrations. Results from a much larger retrospective study showed that patients with COPD had slightly fewer episodes of pneumonia if they had a blood eosinophil count of ≥2% versus <2%, regardless of whether their medication regimen included an ICS. The authors speculated that patients with eosinophil counts ≥2% may have better capacity for clearing the lungs of infections before progressing to pneumonia than patients with <2% eosinophil levels, due to the antimicrobial defense role of eosinophils. Consistent with this proposal, an inverse relationship between bacterial infection and blood eosinophil counts has been observed in patients with COPD in an exacerbated state. This further suggests that the ICS responsiveness observed with higher eosinophil counts may be affected by bacterial levels, with lower levels of infection associated with ICS responsiveness. Indeed, in a recent clinical study, an increase in bacterial load was observed in patients with stable, moderate COPD who received LABA/ICS therapy and had low blood or sputum eosinophils (≤2%) at baseline. Increases were not observed in LABA + ICS-treated patients with higher eosinophil levels at baseline or those treated with LABA alone, regardless of eosinophil level at baseline.

Relationship to lung function

The exact nature of the relationship between eosinophilic inflammation and decrements or rates of decline in lung function in patients with COPD remains unclear. In a small sample of patients with moderate–severe COPD (n=10), lower FEV₁ values were associated with greater sputum concentrations of both eosinophils and eosinophil cationic protein (a biomarker of eosinophil inflammation), potentially suggesting a link between airway eosinophilia and airflow obstruction. Similarly, in comparison with asymptomatic smokers, COPD and chronic bronchitis, defined by an FEV₁ <80% (predicted) in addition to symptoms of chronic bronchitis, has been associated with an increased ratio of activated eosinophils to total eosinophils infiltrating large-airway subepithelia. In COPD patients with emphysema...
In patients with blood eosinophil counts \( \geq 2\% \) of \( \geq 340 \) cells/\( \mu L \) [threshold associated with an increased risk of exacerbations]], they tended to be slightly older and male.^{5}

ICS treatment may have a differential impact on lung function in patients with COPD, depending on whether eosinophil concentrations are normal or elevated. A post hoc analysis from the ISOLDE trial, evaluating fluticasone propionate versus placebo in 751 patients with moderate–severe COPD, reported that ICS-treated patients with elevated blood eosinophils \( \geq 2\% \), but not those with blood eosinophils \( < 2\% \), experienced a significantly lower rate of decline in FEV\(_1\) versus patients treated with placebo \( (P=0.003) \).^{37} These results suggest that lung function in patients with high eosinophil levels is more responsive to ICS therapy.

**ICS-treatment considerations in COPD**

**Role of eosinophils and pneumonia history**

The current thinking on the role of ICS in COPD therapy has evolved, in part because of evidence suggesting an increased risk of pneumonia with ICS treatment in some patients,\(^{44-50}\) in addition to evidence of superior efficacy of a LABA–long-acting muscarinic antagonist (LAMA) combination compared to LABA–ICS in reducing exacerbations.\(^{56}\) The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 strategy recommends use of ICS in combination with a LABA in patients with COPD with exacerbations who have a history of asthma or findings suggestive of asthma–COPD overlap (ACO), or in combination with a LAMA and a LABA in those with further exacerbations despite treatment with dual long acting- bronchodilator therapy.\(^1\) High eosinophil counts may also support use of ICS (in combination with bronchodilator therapy) in COPD; however, the GOLD statement notes the relationship is still under debate, and no specific recommendations for thresholds indicating eosinophilia are provided.\(^1\)

**Impact of eosinophils on responses to ICS therapy**

Across several studies, elevated eosinophil concentrations have been found to predict response to ICS in patients with COPD.\(^9,55,57,90\) In patients with blood eosinophil counts of \( \geq 2\% \), ICS–LABA has significantly reduced exacerbation rates compared with placebo \( (P<0.001) \); Treatment of Inhaled Steroids And Long-Acting \( \beta\), Agonists [TRISTAN] study) and with tiotropium \( (P=0.006; \text{Investigating New Standards For Prophylaxis in Reducing Exacerbations [INSPIRE] study)}.^{95,52} In contrast, there were no significant differences in exacerbation rates between treatments in patients with blood eosinophil counts \( < 2\% \) in either study.\(^49\) In addition, a post hoc analysis of the WISDOM trial showed that patients with high blood eosinophil counts tended to be more sensitive to withdrawal of ICS from a LABA–LAMA–ICS combination and had an increase in exacerbations when ICS therapy was stopped.\(^51\) Exacerbation-rate differences between patients who were maintained on ICS therapy and those who stopped ICS therapy increased with increasing blood eosinophil thresholds; a significant treatment-by-subgroup interaction was seen at the 4% and 5% and 300 and 400 cells/\( \mu L \) thresholds only. The authors suggested that a threshold of \( \geq 4\% \) or \( \geq 300 \) cells/\( \mu L \) may identify patients in whom ICS withdrawal from a triple combination may be detrimental.\(^53\)

In contrast, the Effect of Indacaterol Glycopyrronium vs Fluticasone Salmeterol on COPD Exacerbations (FLAME) study found no association between baseline eosinophil concentration and response to ICS treatment.\(^56\) In this study, the annual rate of exacerbations was lower with indacaterol–glycopyrronium (LABA–LAMA) versus salmeterol–fluticasone (LABA–ICS), independently of baseline blood eosinophil concentration \( (< 2\% \text{ vs } \geq 2\%)\).\(^56\) Subsequent analyses of this study did not indicate a significant difference in the rate of exacerbations between the LABA–LAMA and LABA–ICS groups at higher baseline eosinophil thresholds (ie, \( \geq 3\%, \geq 5\%, \text{ or } \geq 300 \) cells/\( \mu L \)).\(^91\) It would be of interest
to investigate differences in treatment regimens based on high eosinophil levels in patients with a frequent-exacerbator phenotype (ie, $\geq 2$ moderate or severe exacerbations or $\geq 1$ severe [ie, hospitalized] exacerbations in the previous year). Because data analysis by eosinophil threshold in the FLAME study was presented for all exacerbations or combined moderate and severe exacerbations, it would be interesting to examine the results for moderate and for severe exacerbations separately. In that regard, the Copenhagen General Population study reported a significantly greater risk of severe exacerbations, but not of moderate exacerbations, in patients with COPD and a blood eosinophil count of $\geq 3.3\%$ versus $<3.3\%$.33

Patients with ACO
Patients with COPD who also have clinical features associated with asthma have been described as having ACO. The overlap in clinical features varies, with some patients having more asthma symptoms, including evidence of T$_{h}2$-mediated inflammation and increased eosinophils and/or mast cells, whereas others have more COPD symptoms and neutrophilic inflammation.92–94 ACO remains a controversial topic, and some experts consider it an oversimplification, with the entity more likely to comprise a spectrum of diseases and phenotypes than a single disorder.95

At present, there is no clear definition of ACO. The 2017 Global Initiative for Asthma (GINA) strategy report described ACO as a phenotype characterized by persistent airflow limitation with several features usually associated with asthma and several features usually associated with COPD.96

Diagnosis requires similar numbers of these features in asthma and COPD ($\geq 3$ for each). Although the presence of elevated eosinophils in sputum is noted as a usual feature of ACO, no consistent recommendations on thresholds are provided.97–99 In line with this, individual clinical studies may include eosinophil thresholds as part of the definition of ACO, but not as a requirement for the condition.100 However, thresholds for high sputum eosinophils, including both $\geq 2%$24,51 and $\geq 3%$,7,104 have been proposed as clinically relevant in patients with COPD. The latter threshold, $\geq 3\%$ sputum eosinophil level, is consistent with that proposed for the Czech diagnostic criteria for ACO.99

To our knowledge, no published studies have specifically evaluated the relationship between eosinophil thresholds and treatment response to ICS in patients with ACO. Based on recommendations by GINA, however, the therapy for patients identified as having ACO is first to treat for asthma, including use of ICS, until further evaluations are undertaken.96

The most current update (2017) to the Spanish COPD guidelines include specific criteria for identification of ACO.101 To establish a diagnosis, a patient should fulfill the criteria for COPD (35 years of age or older, a smoking history, and a postbronchodilator FEV$_1$/forced vital capacity $<70\%$) and have an asthma diagnosis. In cases in which a diagnosis of asthma cannot be established, a marked response to a bronchodilator (FEV$_1$ $\geq 15\%$ and $\geq 400\text{ mL}$) or an elevated blood eosinophil count of $\geq 300\text{ cells/µL}$ is diagnostic of ACO.101 The most recent Czech Republic COPD guidelines98 and guidelines recently proposed by Cosío et al99 also include specific diagnostic criteria for ACO similar to those in the Spanish guidelines, albeit with the inclusion of a recommended sputum eosinophil threshold concentration $\geq 3\%$ and blood eosinophil threshold concentrations $>5\%$98 in the Czech Republic and Cosío et al guidelines, respectively. Similarly to the 2017 Spanish guidelines, a recently proposed consensus definition included an eosinophil concentration $\geq 300\text{ cells/µL}$ as one possible minor criterion that can be used with major criteria (based on lung function, smoking history, or a history of asthma) to identify ACO.99

Assessing risk with ICS: focus on pneumonia
ICS use is associated with certain risks that should be taken into account when assessing the benefit:risk ratio of ICS therapy. In particular, studies have reported that patients with COPD receiving ICS are at increased risk of developing pneumonia.84–89,102 In addition, potential differences in risk for pneumonia may be affected by the specific ICS used.86,103,104 Therefore, considering a patient’s prior history of pneumonia may be important when choosing ICS therapy as part of the COPD-treatment regimen.

Notably, the 2017 GOLD statement bases COPD treatment recommendations predominantly on the basis of burden of respiratory symptoms and history of exacerbations, while neither pneumonia history nor the presence of eosinophilia is factored into the COPD-treatment algorithm.1 Therefore, we propose a new algorithm for optimizing treatment of COPD patients that takes these factors into consideration (Table 2). For COPD patients with high eosinophil counts and no history of pneumonia, ICS is recommended as part of therapy, as treatment benefits (improved lung function and reduced symptoms and rate of exacerbations)3 are high and risk of pneumonia comparatively low. Whether or not ICS treatment should be recommended in patients with
Table 2 Consideration for inclusion/exclusion of ICS as part of therapy

<table>
<thead>
<tr>
<th>History of pneumonia?</th>
<th>High eosinophil counts</th>
<th>Low eosinophil counts</th>
</tr>
</thead>
<tbody>
<tr>
<td>No history of pneumonia</td>
<td>No history of pneumonia</td>
<td>History of pneumonia uncertain</td>
</tr>
<tr>
<td>High benefit and low risk</td>
<td>High benefit and low risk</td>
<td>No data available to support benefit over risk of using ICS</td>
</tr>
<tr>
<td>History of pneumonia uncertain</td>
<td>History of pneumonia uncertain</td>
<td>Need to weigh benefit/ risk of individual patient</td>
</tr>
<tr>
<td>Need to weigh benefit/ risk of individual patient</td>
<td>History of pneumonia uncertain</td>
<td>High risk with low benefit</td>
</tr>
</tbody>
</table>

Notes: Patients with COPD with exacerbations (≥2 or ≥1 exacerbations leading to hospitalization) based on high/low eosinophils and no history/history of pneumonia. Thresholds for high and low eosinophil counts continue to be explored; currently, there is no agreement on these thresholds. Please refer to the text for discussion. Abbreviation: ICS, inhaled corticosteroid.

COPD with low eosinophil counts with or without a history of pneumonia is still not clear. In the situation of a patient with high eosinophil counts plus a history of pneumonia, the benefits and risks must be evaluated on a case-by-case basis. For example, an ICS may be considered in patients with high eosinophil counts and a history of pneumonia who continue to have exacerbations, particularly those leading to hospitalization, while on dual-bronchodilator therapy, assuming the benefit of decreasing future exacerbations outweighs the potential risks.

Emerging treatments for COPD with eosinophilic inflammation

Several therapeutics targeting eosinophils are in development (Table 3). As previously discussed, IL5 is the principal eosinophilic regulatory cytokine that promotes the differentiation, survival, and activation of eosinophils. Treatments successfully targeting the IL5 pathway to reduce eosinophilic inflammation in asthma are now under investigation in COPD.

Mepolizumab is a humanized monoclonal antibody that targets the IL5 ligand and inhibits IL5-receptor signaling in eosinophils. Mepolizumab was approved by the US Food and Drug Administration (FDA) in 2015 as adjunct treatment in patients with severe asthma and eosinophilic inflammation. Clinical benefits of mepolizumab in patients with eosinophilic asthma include reductions in exacerbation rate and asthma symptoms, improvement in FEV₁, and reduced oral CS use. Although an initial pilot study did not show significant improvement with mepolizumab in lung function or reductions in exacerbations in patients with COPD, results from two Phase III studies showed some improvements in exacerbation frequency in mepolizumab-treated patients who had an eosinophilic phenotype (Table 3).

In both of these Phase III studies, patients had COPD and had experienced moderate or severe exacerbations while using inhaled glucocorticoid-based triple therapy. The primary end point for both studies was the annual rate of exacerbations considered moderate (defined as leading to use of systemic glucocorticoids and/or antibiotics) or severe (defined as leading to hospitalization or death). In METREX, patients were divided into an eosinophilic group (≥150 cells/µL at screening or ≥300 cells/µL anytime during the prior year) and a noneosinophilic group. Among patients with an eosinophilic phenotype, those treated with mepolizumab 100 mg had a significantly lower annual moderate/severe exacerbation rate compared with placebo-treated patients (1.40 vs 1.71; adjusted P=0.04); no treatment difference was observed in the total population. In METRO, all patients were required to have an eosinophilic phenotype (as defined in METREX). Despite this, the annual moderate/severe exacerbation rate was not significantly different for the mepolizumab 100 mg, mepolizumab 300 mg, and placebo-treatment groups (1.19, 1.27, and 1.49, respectively). Together, results from the METREX and METRO studies indicate a role for eosinophils in COPD, but suggest that more study is needed to understand the mechanisms underlying COPD.

Reslizumab is a humanized anti-IL5 monoclonal antibody that was approved by the FDA in 2016 as an add-on maintenance treatment in adult patients with severe asthma and an eosinophilic phenotype. Similarly to mepolizumab, it targets the IL5 ligand. Two 52-week Phase III studies showed that reslizumab significantly reduced asthma exacerbations and increased FEV₁ in patients with eosinophilic asthma (≥400 cells/µL). Reslizumab has yet to be formally evaluated in clinical trials for COPD treatment.

Benralizumab is a humanized, afucosylated, monoclonal antibody targeting the IL5-receptor α-chain. Benralizumab depletes eosinophils through antibody-dependent, cell-mediated cytotoxicity via apoptosis of eosinophils induced by activated natural-killer cells. In Phase III clinical studies in severe eosinophilic asthma (blood eosinophil counts of ≥300 cells/µL or ≥150 to <300 cells/µL), benralizumab significantly reduced the annual rate of exacerbations, increased FEV₁, reduced asthma symptoms, and had significant oral CS-sparing effects. In a Phase IIa trial in patients with COPD with sputum eosinophilia (≥3%), benralizumab treatment did not significantly reduce the annual rate of moderate or severe acute exacerbations. However, significant improvements in FEV₁ were observed.
Table 3 Recent and ongoing trials for monoclonal antibody treatments targeting eosinophils in COPD

<table>
<thead>
<tr>
<th>Agent; target</th>
<th>Study</th>
<th>Regimen</th>
<th>Primary end point</th>
<th>Findings if available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mepolizumab; IL-5</td>
<td>NCT02105961 (METReO): Phase III; efficacy and safety of mepolizumab as an add-on treatment in COPD[105,106,111–113]</td>
<td>100 mg or 300 mg; SC; Q4W (13 injections during a 52 week period) plus standard of care COPD medication, vs placebo plus standard of care</td>
<td>Frequency of moderate/severe exacerbations</td>
<td>Study completed; mepolizumab resulted in reduction in frequency of moderate and severe exacerbations compared to placebo, but the difference was not statistically significant[113]</td>
</tr>
<tr>
<td>Mepolizumab; IL-5</td>
<td>NCT01463644: Phase III; mepolizumab in COPD with eosinophilic bronchitis[137]</td>
<td>750 mg; IV; once per month, vs placebo</td>
<td>Percentage decrease in sputum eosinophils from baseline</td>
<td>Study is completed. Although mepolizumab significantly reduced sputum eosinophils and blood eosinophils compared with placebo, it did not improve lung function or reduce exacerbation rates in COPD with eosinophilia[111]</td>
</tr>
<tr>
<td>Mepolizumab; IL-5</td>
<td>NCT02105948 (MeTReX): Phase III; study to evaluate efficacy and safety of mepolizumab for frequently exacerbating COPD patients[106]</td>
<td>100 mg; SC; Q4W, vs placebo</td>
<td>Frequency of moderate/severe exacerbations</td>
<td>Study completed[106]; mepolizumab resulted in significant reduction in frequency of moderate and severe exacerbations compared to placebo in the eosinophilic group (1.40 vs 1.71 per year, rate ratio 0.82; 95% CI 0.68–0.98; adjusted P=0.04)[113]</td>
</tr>
<tr>
<td>Reslizumab; IL-5</td>
<td>No documented studies in COPD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benralizumab; IL-5 receptor-α</td>
<td>NCT01227278: Phase IIA; a study to evaluate the effectiveness of MEDI563 in subjects with chronic COPD[54,138]</td>
<td>100 mg; Q4W ×3 doses, then Q8W ×5 doses, vs placebo</td>
<td>Annual rate of moderate or severe acute exacerbation of COPD</td>
<td>Study completed. Demonstrated rapid, nearly complete, reversible depletion of sputum and blood eosinophils; also identified subgroup of patients (≥200 or ≥300 eosinophils/µL) who showed greater clinical benefits from benralizumab treatment, though treatment effects did not reach statistical significance[54]</td>
</tr>
<tr>
<td>Benralizumab; IL-5 receptor-α</td>
<td>TERRANOVA (NCT02155660): Phase III; efficacy and safety of benralizumab in adults with moderate–severe COPD with exacerbation history[100]</td>
<td>Dosage not given; SC; schedule not given</td>
<td>Annual COPD-exacerbation rate</td>
<td>Study ongoing, but not currently recruiting participants; estimated primary completion April 2018</td>
</tr>
<tr>
<td>Benralizumab; IL-5 receptor-α</td>
<td>GALATHeA (NCT02138916): Phase III; benralizumab efficacy in moderate–very severe COPD with exacerbation history[106]</td>
<td>Dose not given; SC; schedule not given</td>
<td>Annual COPD-exacerbation rate</td>
<td>Study ongoing, but not currently recruiting participants; estimated primary completion April 2018</td>
</tr>
</tbody>
</table>

(Continued)
in the benralizumab group, and the results of prespecified subgroup analyses by baseline blood eosinophil count with benralizumab versus placebo supported further examination of benralizumab in patients with COPD.\textsuperscript{54} Ongoing Phase III trials evaluating benralizumab in COPD are described in Table 3.

Although IL13 has a more limited role in its scope of effects on eosinophils than IL5, it is a major factor mediating eosinophil recruitment to the lungs.\textsuperscript{126,127} Subcutaneous administration of the anti-IL13 monoclonal antibody lebrikizumab significantly increased mean FEV\textsubscript{1} in asthma patients with high periostin blood concentrations versus placebo in a Phase II study.\textsuperscript{128} However, inconsistent results of lebrikizumab were seen in two recent Phase III studies evaluating its effects on asthma exacerbations (primary end point) in patients with elevated blood biomarkers (\(\geq 50\) ng/mL periostin or \(\geq 300\) eosinophils/\(\mu\)L), with one study (LAVOLTA I) yielding significant reductions in exacerbations and the other (LAVOLTA II) nonsignificant reductions.\textsuperscript{129} A Phase II trial of lebrikizumab has been completed in patients with COPD (Table 3).\textsuperscript{109} The anti-IL13 antibody tralokinumab (300 mg subcutaneously every 2 weeks [Q2W] to week 50 or Q2W to week 12 followed by Q4W to week 48) was investigated in a Phase IIB study (NCT01402986) in patients with severe uncontrolled asthma.\textsuperscript{130} Significant improvements in FEV\textsubscript{1} were observed with the Q2W regimen versus placebo, and post hoc analyses suggested possible benefits of tralokinumab treatment in a defined patient subpopulation (including those with elevated serum dipeptidyl peptidase 4 and/or periostin concentrations).\textsuperscript{130} The potential utility of other antieosinophil targets for treatment of COPD (eg, anti-IL4-receptor monoclonal antibody [dupilumab],\textsuperscript{131} CRTH2 antagonists [OC000459,\textsuperscript{132–135} fevipiprant\textsuperscript{136}]) are yet to be determined, as these agents are not currently being evaluated in COPD.

**Conclusion**

Eosinophils are mediators of inflammation in many patients with COPD. Although a widely accepted threshold to define eosinophilic inflammation in the context of COPD has not been firmly established, elevated eosinophil counts have been associated with reduced lung function and increased risk of exacerbations in patients with COPD. Moreover, a reduction in eosinophilic inflammation is associated with reduced exacerbation frequency. Patients with COPD who have evidence of eosinophilic inflammation generally respond better to ICS treatment. Increased eosinophil counts in the blood may be an acceptable surrogate for airway eosinophilia and may serve as a readily accessible biomarker for ICS-treatment response in COPD. Emerging therapies targeting eosinophil chemotactic and survival factors, such as monoclonal antibodies targeting the IL5 ligand, the IL5 receptor, IL4 receptor, and the IL13 ligand, have been studied in asthma, and some are beginning to be studied in COPD, where they may prove to be effective treatments.

**Acknowledgments**

We thank Beverly E Barton, PhD, Devin S Gary, PhD, and Stella Chow, PhD of Scientific Connexions, an Ashfield company, part of UDG Healthcare PLC (Lyndhurst, NJ, USA), and Courtney St Amour, PhD, of MedErgy Health Group Inc (Yardley, PA, USA) for medical writing support funded by AstraZeneca LP (Wilmington, DE, USA).

**Author contributions**

Both authors contributed to the development and critical revision of this manuscript, approved the final version to be
published, and agree to be accountable for all aspects of the information contained in this review.

Disclosure

DPT has served on advisory boards for AstraZeneca, Novartis, and Sunovion, as a speaker for Boehringer-Ingelheim, and as a consultant for Theravance/Innoviva. MEW has served as a consultant for Ambit Bioscience, AstraZeneca, Boehringer-Ingelheim, BSCI, Genentech, Gilacure, GlaxoSmithKline, Meda, Mylan, Neurotronic, Novartis, Regeneron, Sanofi, Sunovion, Teva, Theravance, Tunitas, and Vectura, received research funding from Sanofi, served on an advisory board for Teva, was a DSMB member for Sentien, and received honoraria from BSCI. The authors report no other conflicts of interest in this work.

References


35. Tashkin and wechsler


